CHLOROANILINE DERIVATIVES

Abstract: The invention provides compounds of the general formula (I) and physiologically acceptable salts and solvates thereof, wherein Q represents a chlorine atom or a trifluoromethyl group; X represents a bond, or a C₁₋₆alkylene, C₂₋₆alkenylene or C₂₋₆alkynylene chain, and Y represents a bond, or a C₁₋₆alkylene, C₂₋₆alkenylene or C₂₋₆alkynylene chain with the proviso that the sum total or carbon atoms in the chains X and Y is not more than 10, and the chains XCH₂ and CH₂Y may each be optionally substituted by one or two C₁₋₃alkyl groups, or, when one carbon atom is substituted by two alkyl groups, these may be linked to form an alkylene group; R represents a hydrogen atom or a C₁₋₃alkyl group; R¹ and R² each represent a hydrogen atom or a C₁₋₃alkyl group, with the proviso that the sum total of carbon atoms in R¹ and R² is not more than 4; and Het represents a benzoheteroaryl or a monocyclic heteroaryl group wherein the heteroaryl group is 5 or 6 membered and contains 1, 2 or 3 hetero atoms, one of which is a nitrogen atom and the other(s) is (are) nitrogen, oxygen or sulphur atom(s), and the group Het may optionally be substituted by one or two groups selected from C₁₋₄alkyl, C₁₋₄alkoxy, hydroxy, halogen, -NR³R⁴ and -COR⁸; where R³ and R⁴ each represent a hydrogen atom or a C₁₋₄alkyl group or -NR³R⁴ forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from -O- or -S- or a group -NH- or -N(CH₃)-; and R⁸ represents hydroxy, C₁₋₄alkoxy or -NR³R⁴; with the proviso that (i) when Het represents a pyridyl group substituted by the group -NR³R⁴ or -COR⁸ and Q is a chlorine atom, or (ii) when Het represents a pyridyl group optionally substituted by one or two groups selected from halogen, hydroxy, C₁₋₃alkyl and C₁₋₃alkoxy, and Y represents a bond or a C₁₋₄alkylene, C₂₋₄alkenylene or C₂₋₄alkynylene chain, then, in both cases, R represents a C₁₋₃alkyl group and/or at least one of the chains -XCH₂- and -CH₂Y- is substituted by one or two C₁₋₃alkyl groups. The compounds have a stimulant action at β2-­ adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

Description: This invention relates to chloroaniline derivatives having a stimulant action at β₂-adrenoreceptors, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. Chloroaniline derivatives have previously been described as bronchodilators having stimulant activity at β-adrenoreceptors. Thus, British Patent Specification No. 1178191 describes compounds of the general structure in which the substituents Hal represent bromine or chlorine atoms; R¹ represents hydrogen or hydroxyl; R² and R³ each represent hydrogen or C₁₋₄ alkyl; and R⁴ and R⁵ each represent hydrogen, C₁₋₆ alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, phenyl, benzyl or adamantyl radicals, or NR⁴R⁵ forms a heterocyclic ring optionally substituted by C₁₋₃ alkyl groups. UK Patent Specification Nos. 2165542A and 2182658A describe compounds of the general structure in which R¹ and R² each represent hydrogen or C₁₋₃ alkyl; X represents C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene; Y represents C₁₋₄ alkylene, C₂₋₄ slkenylene or C₂₋₄ alkynylene; and Ar represents a phenyl group optionally substituted by one or more of a variety of specific substituents. We have now found a novel group of compounds which differ structurally from those described in British Patent Specification No. 1178191 and UK Patent Specification Nos. 2165542A and 2182658A, and which have a desirable and useful profile of activity. Thus the present invention provides compounds of the general formula (I) and physiologically acceptable salts and solvates (e.g. hydrates) thereof, wherein X represents a C₃₋₄ alkylene chain, and Y represents a C₁₋₅ alkylene chain; Het represents a thiazolyl group optionally substituted by one or two groups selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, halogen, -NR³R⁴ and -COR⁸; where R³ and R⁴ each represent a hydrogen atom or a C₁₋₄alkyl group or -NR³R⁴ forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from -O- or -S- or a group -NH- or -N(CH₃)-; and R⁸ represents hydroxy, C₁₋₄ alkoxy or -NR³R⁴. It will be appreciated that the compounds of general formula (I) possess one or more asymmetric carbon atoms. The compounds according to the invention thus include all enantiomers, diastereoisomers and mixtures thereof, including racemates. Compounds in which the carbon atom in the group is in the R configuration are preferred. In the definition of general formula (I), the term alkenylene includes both cis and trans structures. In the general formula (I), the chain XCH₂ may be -(CH)₂)₄-₅ OR -(CH₂)₅-. The chain CH₂Y may be -(CH₂)₂-, -(CH₂)₃-, -(CH₂)₄-, -(CH₂)₅- OR -(CH₂)₆-. Particular compounds (I) are those wherein X represents -(CH₂)₄- and Y represents -(CH₂)₂-, -(CH₂)₄ or -(CH₂)₅-. The group Het is attached to the rest of the molecule through any available position in the thiazolyl ring. Any substituent(s) in the group Het may be at any available position(s) in the thiazolyl ring. When the group Het is substituted by one or two halogen atoms, these may be chlorine, fluorine or bromine. When -NR³R⁴ represents a saturated heterocyclic amino group, this may be, for example, a pyrrolidiono, piperidino, hexamethyleneimino, piperazino, N-methylpiperazino, morpholino, homomorpholino or thiamorpholino group. A preferred compound according to the invention is 4-amino-3,5-dichloro-α-[[[6-[3-(2-thiazolyl)propoxy]hexyl]amino]methyl]benzenemethanol; and its physiologically acceptable salts and solvates. Suitable physiologically acceptable salts of the compounds of general formula (I) include acid addition salts derived from inorganic and organic acids, such as hydrochlorides, hydrobromides, sulphates, phosphates, maleates, tartrates, citrates, benzoates, 4-methoxybenzoates, 2- or 4-hydroxybenzoates, 4-chlorobenzoates, benzenesulphonates, p-toluenesulphonates, naphthalenesulphonates, methanesulphonates, sulphamates, ascorbates, salicylates, acetates, diphenylacetates, triphenylacetates, adipates, fumarates, succinates, lactates, glutarates, gluconates, tricarballylates, hydroxy-naphthalenecarboxylates e.g. 1-hydroxy- or 3-hydroxy-2-naphthalenecarboxylates, or oleates. The compounds may also form salts with suitable bases where appropriate. Examples of such salts are alkali metal (e.g. sodium and potassium) and alkaline earth metal (e.g. calcium or magnesium) salts, and salts with organic bases (e.g. triethylamine). The compounds according to the invention have a stimulant action at β₂-adrenoreceptors, which furthermore is of a particularly advantageous profile. The stimulant action was demonstrated in the isolated trachea of the guinea-pig, where compounds were shown to cause relaxation of contractions induced by PGF₂α or electrical stimulation. Compounds according to the invention have shown a particularly long duration of action in these tests. The compounds according to the invention may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis. The compounds according to the invention are also indicated as useful for the treatment of inflammatory and allergic skin diseases, congestive heart failure, depression, premature labour, glaucoma, and in the treatment of conditions in which there is an advantage in lowering gastric acidity, particularly in gastric and peptic ulceration. The invention accordingly further provides compounds of formula (I) and their physiologically acceptable salts and solvates for use in the therapy or prophylaxis of diseases associated with reversible airways obstruction in human or animal subjects. The compounds according to the invention may be formulated for administration in any convenient way. The invention therefore includes within its scope pharmaceutical compositions comprising at least one compound of formula (I) or a physiologically acceptable salt or solvate thereof formulated for use in human or veterinary medicine. Such compositions may be presented for use with physiologically acceptable carriers or excipients, optionally with supplementary medicinal agents. The compounds may be formulated in a form suitable for administration by inhalation or insufflation, or for oral, buccal, parenteral, topical (including nasal) or rectal administration. Administration by inhalation or insufflation is preferred. For administration by inhalation the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas, or from a nebuliser. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in for example capsules or cartridges of e.g. gelatin, or blister packs from which the powder may be administered with the aid of an inhaler or insufflator. For oral administration, the pharmaceutical composition may take the form of, for example, tablets, capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients. For buccal administration the composition may take the form of tablets, drops or lozenges formulates in conventional manner. The compounds of the invention may be formulates for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form in ampoules, or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use. For topical administration the pharmaceutical composition may take the form of ointments, lotions or creams formulated in a conventional manner, with for example an aqueous or oily base, generally with the addition of suitable thickening agents and/or solvents. For nasal application, the composition may take the form of a spray, formulated for example as an aqueous solution or suspension or as an aerosol with the use of a suitable propellant. The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glyceride. Where pharmaceutical compositions are described above for oral, buccal, rectal or topical administration, these may be presented in a conventional manner associated with controlled release forms. A proposed daily dosage of active compound for the treatment of man is 0.05mg to 100mg, which may be conveniently administered in one or two doses. The precise dose employed will of course depend on the age and condition of the patient and on the route of administration. Thus a suitable dose for administration by inhalation is 0.005mg to 20mg, for oral administration is 0.02mg to 100mg, and for parenteral administration is 0.01mg to 2mg for administration by bolus injection and 0.01mg to 25mg for administration by infusion. The compounds according to the invention may be prepared by a number of processes. In the following description, X, Y and Het, are as defined for general formula (I) unless otherwise specified. In the preparation of both intermediates and end-products the final step in the reaction may be the removal of a protecting group. Suitable protecting groups and their removal are described in general process (3) below. In one general process (1), a compound of general formula (I) may be prepared by alkylation. Conventional alkylation procedures may be used. Thus, for example, in one process (a), a compound of general formula (I) may be prepared by alkylation of an amine of general formula (II) (wherein R⁵ is a hydrogen atom or a protecting group and R⁶ is a hydrogen atom) followed by removal of any protecting group where present. The alkylation (a) may be effected using an alkylating agent of general formula (III): LCH₂XCH₂OCH₂Y-Het (III) (wherein L is a leaving group, for example a halogen atom such as chlorine, bromine or iodine, or a hydrocarbylsulphonyloxy group such as methanesulphonyloxy or p-toluenesulphonyloxy). The alkylation is preferably effected in the presence of a suitable acid scavenger, for example, inorganic bases such as sodium or potassium carbonate, organic bases such as triethylamine, diisopropylethylamine or pyridine, or alkylene oxides such as ethylene oxide or propylene oxide. The reaction is conveniently effected in a solvent such as acetonitrile or an ether e.g. tetrahydrofuran or dioxan, a ketone e.g. butanone or methyl isobutyl ketone, a substituted amide e.g. dimethylformamide or a chlorinated hydrocarbon e.g. chloroform, at a temperature between ambient and the reflux temperature of the solvent. According to another example (b) of an alkylation process, a compound of general formula (I) may be prepared by alkylation of an amine of general formula (II), as previously defined except that R⁶ is a hydrogen atom or a group convertible thereto under the reaction conditions, with a compound of general formula (IV): HCOXCH₂OCH₂Y-Het (IV) in the presence of a reducing agent, followed when necessary by removal of any protecting groups. Examples of suitable R⁶ groups convertible into a hydrogen atom are arylmethyl groups such as benzyl, α-methylbenzyl and benzhydryl. Suitable reducing agents include hydrogen in the presence of a catalyst such as platinum, platinum oxide, palladium, palladium oxide, Raney nickel or rhodium, on a support such as charcoal, using an alcohol, e.g. ethanol or methanol, or an ester e.g. ethyl acetate, or an ether e.g. tetrahydrofuran, or water, as reaction solvent, or a mixture of solvents, e.g. a mixture of two or more of those just described, at normal or elevated temperature and pressure, for example from 20 to 100°C and from 1 to 10 atmospheres. Alternatively when one or both of R⁵ and R⁶ are hydrogen atoms, the reducing agent may be a hydride such as diborane or a metal hydride such as sodium borohydride, sodium cyanoborohydride or lithium aluminium hydride. Suitable solvents for the reaction with these reducing agents will depend on the particular hydride used, but will include alcohols such as methanol or ethanol, or ethers such as diethyl ether or tert -butyl methyl ether, or tetrahydrofuran. When a compound of formula (II) where R⁵ end R⁶ are each hydrogen atoms is used, the intermediate imine of formula (V) may be formed: Reduction of the imine using the conditions described above, followed, where necessary, by removal of any protecting groups, gives a compound of general formula (I). In another general process (2) compounds of formula (I) may be prepared by reducing an intermediate of general formula (VI): wherein at least one of X¹, X², X and Y represents a reducible group and the other(s) take the appropriate meaning as follows, which is X¹ is -CH(OH)-, X² is -CH₂NR⁵- (where R⁵ represents a hydrogen atom or a protecting group), and X and Y are as defined in formula (I), followed where necessary by removal of any protecting groups. Suitable reducible groups include those wherein X¹ is a group C=O, X² is a group -CH₂NR⁷- (wherein R⁷ represents a group convertible to hydrogen by catalytic hydrogenation, for example an arylmethyl group such as benzyl, benzhydryl or α-methylbenzyl). The reduction may be effected using reducing agents conveniently employed for the reduction of ketones or protected amines. Thus, for example, when X¹ in general formula (VI) represents a C=O group this may be reduced to a -CH(OH)- group using hydrogen in the presence of a catalyst such as platinum, platinum oxide, palladium, palladium oxide, Raney nickel or rhodium, on a support such as charcoal, using an alcohol e.g. ethanol, an ester e.g. ethyl acetate, an ether e.g. tetrahydrofuran, or water, as reaction solvent, or a mixture of solvents, e.g. a mixture of two or more of those just described, at normal or elevated temperature and pressure, for example from 20 to 100°C and from 1 to 10 atmospheres. Alternatively, the reducing agent may be, for example, a hydride such as diborane or a metal hydride such as lithium aluminium hydride, sodium bis(2-methoxyethoxy) aluminium hydride, sodium borohydride or aluminium hydride. The reaction may be effected in an appropriate solvent, such as an alcohol e.g. methanol or ethanol, or an ether such as tetrahydrofuran, or a halogenated hydrocarbon such as dichloromethane. When X² in general formula (VI) represents a -CH₂NR⁷- group this may be reduced to a -CH₂NH- group using hydrogen in the presence of a catalyst as described above. Where it is desired to use a protected intermediate of general formula (VI) it is particularly convenient to use a protecting group R⁵ which is capable of being removed under the reducing conditions, for example hydrogen and a catalyst, thus avoiding the need for a separate deprotection step. Suitable protecting groups of this type include arylmethyl groups such as benzyl, benzhydryl and α-methylbenzyl. In a further process (3) compounds of formula (I) may be prepared by deprotecting an intermediate of general formula (VII) wherein R⁵ is a protecting group and/or the group Het contains a protecting group. The protecting group may be any conventional protecting group as described for example in "Protective Groups in Organic Chemistry", by Theodora Greene (John Wiley and Sons Inc, 1981). Thus, for example, hydroxy groups may be protected by arylmethyl groups such as benzyl, diphenylmethyl or triphenylmethyl, by acyl groups such as acetyl, or as tetrahydropyranyl derivatives. Examples of suitable amino protecting groups include arylmethyl groups such as benzyl, α-methylbenzyl, diphenylmethyl or triphenylmethyl, and acyl groups such as acetyl, trichloroacetyl or trifluoroacetyl. The deprotection to yield a compound of general formula (I) may be effected using conventional techniques. Thus for example arylmethyl groups may be removed by hydrogenolysis in the presence of a metal catalyst (e.g. palladium on charcoal). Tetrahydropyranyl groups may be cleaved by hydrolysis under acidic conditions. Acyl groups may be removed by hydrolysis with an acid such as a mineral acid e.g. hydrochloric acid, or a base such as sodium hydroxide or potassium carbonate, and a group such as trichloroacetyl may be removed by reduction with, for example, zinc and acetic acid. Intermediates of formula (VI) for use in the reduction process (2) in which X¹ is the group C=O may be prepared by reaction of a haloketone of formula (VIII) (where Hal represents a halogen atom e.g. bromine) with an amine of formula (IX) R⁵NHCH₂XCH₂OCH₂Y-Het (IX) (where R⁵ is a hydrogen atom or a group convertible thereto by catalytic hydrogenation). The reaction may be effected in a cold or hot solvent, for example tetrahydrofuran, tert-butyl methyl ether, dioxan, chloroform, dichloromethane, dimethylformamide, acetonitrile, a ketone such as butanone or methylisobutylketone, or an ester such as ethyl acetate, preferably in the presence of a base such as diisopropylethylamine, sodium carbonate or other acid scavenger such as propylene oxide. Intermediates of general formula (VI) in which X¹ is the group C=O may be reduced to the corresponding intermediate in which X¹ is the group -CH(OH)- using for example a metal hydride such as sodium borohydride in a solvent e.g. ethanol, methanol and/or tetrahydrofuran. Amines of formula (II) and haloketones of formula (VIII) are either known compounds or may be prepared by methods analogous to those described for the preparation of known compounds. Suitable methods for preparing intermediates of formulae (III), (IV) and (IX) are described in UK Patent Specification Nos. 2140800A and 2159151A and in the exemplification included hereinafter. In the general processes described above, the compound of formula (I) obtained may be in the form of a salt, conveniently in the form of a physiologically acceptable salt. Where desired, such salts may be converted to the corresponding free bases using conventional methods. Physiologically acceptable salts of the compounds of general formula (I) may be prepared by reacting a compound of general formula (I) with an appropriate acid or base in the presence of a suitable solvent such as acetonitrile, acetone, chloroform, ethyl acetate or an alcohol, e.g. methanol, ethanol or isopropanol. Physiologically acceptable salts may also be prepared from other salts, including other physiologically acceptable salts, of the compounds of general formula (I), using conventional methods. When a specific enantiomer of a compound of general formula (I) is required, this may be obtained by resolution of a corresponding racemate of a compound of general formula (I) using conventional methods. Thus, in one example an appropriate optically active acid may be used to form salts with the racemate of a compound of general formula (I). The resulting mixture of isomeric salts may be separated for example by fractional crystallisation, into the diastereoisomeric salts from which the required enantiomer of a compound of general formula (I) may be isolated by conversion into the required free base. Alternatively, enantiomers of a compound of general formula (I) may be synthesised from the appropriate optically active intermediates using any of the general processes described herein. Specific diastereoisomers of a compound of formula (I) may be obtained by conventional methods for example, by synthesis from an appropriate asymmetric starting material using any of the processes described herein, or by conversion of a mixture of isomers of a compound of general formula (I) into appropriate diastereoisomeric derivatives e.g. salts which then can be separated by conventional means e.g. by fractional crystallisation. The following examples illustrate the invention. Temperatures are in °C. 'Dried' refers to drying of organic extracts using magnesium sulphate or sodium sulphate. Unless otherwise stated, thin layer chromatography (t.l.c.) was carried out on silica and flash column chromatography (FCC) on silica (Merck 9385) using one of the following solvent systems : A-toluene:ethanol:0.88 ammonia, B-toluene:ethanol:triethylamine, C-diethyl ether:methanol. The following abbreviations are used : THF - tetrahydrofuran, DMF - dimethylformamide, BTPC - bis(triphenylphosphine)palladium (II) chloride, TAB - tetra-n-butylammonium hydrogen sulphate, DEA - N,N-diisopropylethylamine. Intermediate 1 is 4-amino-α-(aminomethyl)-3,5-dichlorobenzenemethanol. Intermediate 2 4-[2-[(6-Bromohexyl)oxy]ethyl]-2-methylthiazole A mixture of 2-methyl-4-thiazoleethanol (2.22g), 1,6-dibromohexane (7.1mℓ) 12.5M aqueous sodium hydroxide (4mℓ) and TAB (0.1g) was stirred rapidly at room temperature for 16h. The reaction mixture was diluted with water (30mℓ), extracted with ether (3x30mℓ) and the combined organic extracts were washed with water (30mℓ) and brine (30mℓ), dried and concentrated. The residual oil was purified by FCC eluting with diethyl ether-hexane (1:3) to give the title compound as an orange oil (2.21g), t.l.c. (ether - hexane 1:3) Rf 0.17 Intermediate 3 3-[(2-Thiazolyl)]-2-propynol Copper (I) iodide (28.5mg) was added to a stirred solution of 2-bromothiazole (5g), propargyl alcohol (1.68g), BTPC (210mg) and DEA (2.41g) in acetonitrile (88mℓ). The mixture was stirred under nitrogen for 80h, concentrated and partitioned between ethyl acetate (100mℓ) and water (100mℓ). The organic layer was dried and concentrated to yield the crude product which was purified by FCC eluting with toluene/ethyl acetate (5:2) to give the title product as a brown oil (0.68g), t.l.c. (toluene/ethyl acetate 2:1) Rf 0.27. Intermediate 4 2-Thiazolepropanol Glacial acetic acid (16mℓ) was added dropwise during 0.25h to a stirred solution of 3-(2-thiazolyl)-2-propynol (2.4g) and dipotassium azodicarboxylate (50g) in pyridine (200mℓ). The mixture was stirred at room temperature for 1h and additional glacial acetic acid (40mℓ) added during 0.5h. The mixture was stirred at room temperature for 2 days. The solvent was removed by azeotropic distillation with toluene (2x100mℓ) and the residue partitioned between water (100mℓ) and ethyl acetate (100mℓ). The aqueous layer was extracted with ethyl acetate (2x50mℓ) and the combined extracts dried and evaporated to leave a brown oil. This was purified by FCC eluting with toluene:ethyl acetate:triethylamine (50:50:1) to give the title compound as an orange oil (1.45g), t.l.c. (toluene:ethyl acetate:triethylamine 50:50:1) Rf 0.15. Intermediate 5 2-[[(6-Bromohexyl)oxy]propyl]thiazole A mixture of 2-thiazolepropanol (1.45g) 1,6-dibromohexane (7.4g), TAB (125mg) and 50% w/v sodium hydroxide solution (5mℓ) was stirred at room temperature for 6h, diluted with water (50mℓ) and extracted with ether (3x50mℓ). The combined, dried extracts were evaporated and the residue was purified by FCC eluting with toluene followed by System B (98:2:1), to give the title compound as a pale yellow oil (1.76g), t.l.c. (System B 95:5:1) Rf 0.55. Example 1 4-Amino-3,5-dichloro-α-[[[6-[2-(2-methyl-4-thiazolyl)ethoxy]hexyl] amino]methyl]benzenemethanol From 4-[2-[(6-bromohexyl)oxy]ethyl]-2-methylthiazole (1.2g) and Intermediate 1 (1.30g), heating the reaction mixture for 1.5hr. FCC eluting with System B (97:3:1) gave an oil which when triturated with hexane gave the title compound as a white solid (0.78g) m.p. 67-69°. Analysis Found: C,53.9; H,6.6; N,9.3; Cl,15.7; S,7.2. C₂₀H₂₉Cl₂N₃O₂S requires C,53.8; H,6.6; N,9.4; Cl,15.9; S,7.2% Example 2 4-Amino-3,5-dichloro-α-[[[6-[3-(2-thiazolyl)propoxy]hexyl]amino] methyl]benzenemethanol, (E) butenedioate salt (2:1) A mixture of 4-amino-α(aminomethyl)-3,5-dichlorobenzenemethanol (800mg), 2-[[(6-bromohexyl)oxy]propyl]thiazole (739mg) and DEA (390mg) in dry DMF (10mℓ) was heated at 80° for 2h under nitrogen. The solvent was evaporated and the residue purified by FCC eluting with System B (95:5:1) to give the base as a pale yellow oil (615mg). A solution of the oil in methanol (5mℓ) was treated with a solution of fumaric acid (80mg) in methanol (5mℓ). The solvent was evaporated off and the residue triturated under ether (10mℓ) to give the title compound as a white powder (560mg), m.p. 113-4°. Analysis Found: C,51.9; H,5.9; N,8.0; S,6.0; Cl,13.2 C₂₀H₂₉Cl₂N₃O₂S.O.5C₄H₄O₄.O.5H₂O requires C,51.5; H,6.3; N,8.2; S,6.2; Cl,13.8%. The following are examples of suitable formulations of compounds of the invention. The term 'active ingredient' is used herein to represent a compound of the invention. Tablets (Direct Compression) mg/tablet Active ingredient 2.0 Microcrystalline cellulose USP 196.5 Magnesium Stearate BP 1.5 Compression weight 200.0 The active ingredient is sieved through a suitable sieve, blended with the excipients and compressed using 7mm diameter punches. Tablets of other strengths may be prepared by altering the ratio of active ingredient to microcrystalline cellulose or the compression weight and using punches to suit. The tablets may be film coated with suitable film forming materials, such as hydroxypropylmethylcellulose, using standard techniques. Alternatively, the tablets may be sugar coated. Metered Dose Pressurised Aerosol (Suspension Aerosol) mg/metered dose Per can Active ingredient micronised 0.100 26.40mg Oleic Acid BP 0.010 2.64mg Trichlorofluoromethane BP 23.64 5.67g Dichlorodifluoromethane BP 61.25 14.70g The active ingredient is micronised in a fluid energy mill to a fine particle size range. The oleic acid is mixed with the trichlorofluoromethane at a temperature of 10-15°C and the micronised drug is mixed into the solution with a high shear mixer. The suspension is metered into aluminium aerosol cans and suitable metering valves delivering 85mg of suspension are crimped onto the cans and the dichlorodifluoromethane is pressure filled into the cans through the valves. Inhalation Cartridges mg/cartridge Active ingredient micronised 0.200 Lactose BP to 25.0 The active ingredient is micronised in a fluid energy mill to a fine particle size range prior to blending with normal tabletting grade lactose in a high energy mixer. The powder blend is filled into No. 3 hard gelatin capsules on a suitable encapsulating machine. The contents in the cartridges are administered using a powder inhaler such as the Glaxo Rotahaler.

Claims: Claims for the following Contracting States: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE Compounds of the general formula (I) and physiologically acceptable salts and solvates thereof, wherein X represents a C₃₋₄alkylene chain, Y represents a C₁₋₅alkylene chain, and Het represents a thiazolyl group, optionally substituted by one or two groups selected from C₁₋₄alkyl, C₁₋₄alkoxy, hydroxy, halogen, -NR³R⁴ and -COR⁸; where R³ and R⁴ each represent a hydrogen atom or a C₁₋₄alkyl group or -NR³R⁴ forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from -O-, -S- or a group -NH- or -N(CH₃)-; and R⁸ represents hydroxy, C₁₋₄alkoxy or -NR³R⁴. 4-Amino-3,5-dichloro-α-[[[6-[3-(2-thiazolyl)propoxy]hexyl] amino]methyl]benzenemethanol; and physiologically acceptable salts and solvates thereof. 4-Amino-3,5-dichloro-α-[[[6-[3-(2-thiazolyl)propoxy]hexyl]amino] methyl]benzenemethanol, (E) butenedioate salt. A process for the preparation of compounds as claimed in any one of claims 1 to 3 or a physiologically acceptable salt or solvate thereof which comprises (1a) alkylating an amine of general formula (II) (in which R⁵ is a hydrogen atom or a protecting group and R⁶ is a hydrogen atom) with an alkylating agent of formula (III) LCH₂XCH₂OCH₂Y-Het (III) (in which L is a leaving group), followed, if necessary, by removal of any protecting group present; or (1b) alkylating an amine of general formula (II) as defined above except that R⁶ is a hydrogen atom or a group convertible thereto under the reaction conditions, with a compound of general formula (IV) HCOXCH₂OCH₂Y-Het (IV) in the presence of a reducing agent, followed, if necessary, by the removal of any protecting group present; or (2) reducing an intermediate of general formula (VI) in which X¹ is -CH(OH)- or a group convertible thereto by reduction; X² is -CH₂NR⁵- (where R⁵ represents a hydrogen atom or a protecting group) or a group convertible thereto by reduction; and X and Y are as defined in formula (I); at least one of X¹, X², X and Y representing a reducible group, followed, if necessary, by removal of any protecting group present; or (3) deprotecting a protected intermediate of general formula (VII) in which R⁵ is a protecting group and/or the group Het contains a protecting group; and when the compound of general formula (I) is obtained as a mixture of enantiomers, optionally resolving the mixture to obtain the desired enantiomer; and/or, if desired, converting the resulting compound of general formula (I) or a salt thereof into a physiologically acceptable salt or solvate thereof. A pharmaceutical composition comprising at least one compound of general formula (I) as defined in any one of claims 1 to 3 or a physiologically acceptable salt or solvate thereof, together with at least one physiologically acceptable carrier or excipient. Claims for the following Contracting States: ES, GR A process for the preparation of compounds of the general formula (I) and physiologically acceptable salts and solvates thereof, wherein X represents a C₃₋₄alkylene chain, Y represents a C₁₋₅alkylene chain, and Het represents a thiazolyl group, optionally substituted by one or two groups selected from C₁₋₄alkyl, C₁₋₄alkoxy, hydroxy, halogen, -NR³R⁴ and -COR⁸; where R³ and R⁴ each represent a hydrogen atom or a C₁₋₄alkyl group or -NR³R⁴ forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from -O-, -S- or a group -NH- or -N(CH₃)-; and R⁸ represents hydroxy, C₁₋₄alkoxy or -NR³R⁴; which comprises: (1a) alkylating an amine of general formula (II) (in which R⁵ is a hydrogen atom or a protecting group and R⁶ is a hydrogen atom) with an alkylating agent of formula (III) LCH₂XCH₂OCH₂Y-Het (III) (in which L is a leaving group), followed, if necessary, by removal of any protecting group present; or (1b) alkylating an amine of general formula (II) as defined above except that R⁶ is a hydrogen atom or a group convertible thereto under the reaction conditions, with a compound of general formula (IV) HCOXCH₂OCH₂Y-Het (IV) in the presence of a reducing agent, followed, if necessary, by the removal of any protecting group present; or (2) reducing an intermediate of general formula (VI) in which X¹ is -CH(OH)- or a group convertible thereto by reduction; X² is -CH₂NR⁵- (where R⁵ represents a hydrogen atom or a protecting group) or a group convertible thereto by reduction; and X and Y are as defined in formula (I); at least one of X¹, X², X and Y representing a reducible group, followed, if necessary, by removal of any protecting group present; or (3) deprotecting a protected intermediate of general formula (VII) in which R⁵ is a protecting group and/or the group Het contains a protecting group; and when the compound of general formula (I) is obtained as a mixture of enantiomers, optionally resolving the mixture to obtain the desired enantiomer; and/or, if desired, converting the resulting compound of general formula (I) or a salt thereof into a physiologically acceptable salt or solvate thereof. A process as claimed in claim 1 for the preparation of the compound: 4-Amino=3,5-dichloro-α-[[[6-[3-(2-thiazolyl)propoxy]hexyl]amino]methyl]benzenemethanol; and physiologically acceptable salts and solvates thereof. A process as claimed in claim 1 for the preparation of the compound: 4-Amino-3,5-dichloro-α-[[[6-[3-(2-thiazolyl)propoxy]hexyl]amino]methyl]benzenemethanol, (E) butenedioate salt.

Inventors: LUNTS, LAWRENCE HENRY CHARLES
Applicants: GLAXO GROUP LIMITED
Application year: 1988
Main classification: C07D239
IPC codes: C07D263, A61K31, A61P17, C07D215, C07D213, C07D521, C07D251, C07D235, C07D239, A61P25, A61P1, C07D277, C07D241, A61P11, A61P9, A61P27